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Abstract
Background: Although blinatumomab, a bispecific T cell engaging antibody, exhibits high clinical response rates in
patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin’s
lymphoma (B-NHL), it still has some limitations because of its short half-life. Mesenchymal stromal cells (MSCs)
represent an attractive approach for delivery of therapeutic agents to cancer sites owing to their tropism towards
tumors, but their immunosuppression capabilities, especially induced by indoleamine 2,3-dioxygenase (IDO), should
also be taken into consideration.
Methods: Human umbilical cord-derived MSCs (UC-MSCs) were genetically modified to secrete Tandab (CD3/CD19), a
tetravalent bispecific tandem diabody with two binding sites for CD3 and two for CD19. The tropism of MSCs towards
Raji cells in vitro was determined by migration assays, and the homing property of MSCs in vivo was analyzed with
firefly luciferase-labeled MSCs (MSC-Luc) by bioluminescent imaging (BLI). The cytotoxicity of T cells induced by MSC-
secreting Tandab (CD3/CD19) was detected in vitro and in vivo in combination with D-1-methyl-tryptophan (D-1MT),
an IDO pathway inhibitor.
Results: The purified Tandab (CD3/CD19) was functional with high-binding capability both for CD3-positive cells and
CD19-positive cells and was able to induce specific lysis of CD19-positive cell lines (Raji, Daudi, and BJAB) in the
presence of T cells. Additionally, results from co-culture killing experiments demonstrated that Tandab (CD3/CD19)
secreted from MSCs was also effective. Then, we confirmed that D-1MT could enhance the cytotoxicity of T cells
triggered by MSC-Tandab through reversing T cell anergy with down-regulation of CD98 and Jumonji and restoring
the proliferation capacity of T cells. Furthermore, MSC-Luc could selectively migrate to tumor site in a BALB/c nude
mouse model with Raji cells. And mice injected with MSC-Tandab in combination with D-1MT significantly inhibited
the tumor growth.
Conclusions: These results suggest that UC-MSCs releasing Tandab (CD3/CD19) is an efficient therapeutic tool for the
treatment of B cell lymphoma when combined with D-1MT.
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Background
During the past two decades, therapeutic antibodies
have started to make major contributions to the treat-
ment of B cell malignancies. In 1997, rituximab (a genet-
ically engineered monoclonal chimeric antibody directed
against the CD20 B cell antigen) was approved by the
US Food and Drug Administration (FDA) for the indica-
tion of follicular lymphoma and low-grade B cell non-
Hodgkin’s lymphoma (B-NHL) [1]. However, cancer
relapse and metastasis often occurred after medical
intervention with CD20-based therapy in patients with
follicular lymphoma and acute lymphocytic leukemia [2].
Thus, it is absolutely critical to develop new therapeutic
regimens to overcome these challenges.
T cells are the most potent tumor-killing effector cells,
but they cannot be recruited by conventional antibodies.
However, several bispecific antibodies (bsAbs) that re-
cruit T cells have been developed [3], which may have
the potential to circumvent this problem. To date, the
most promising for the therapeutic application of this
approach is blinatumomab, a tandem single-chain vari-
able fragment (scFv) bsAb in a bispecific T cell engager
(BiTE) format targeting CD19/CD3, which was approved
by the FDA for the treatment of B-precursor acute
lymphoblastic leukemia (B-ALL) [4]. Although blinatu-
momab has impressive efficacy in the clinic and exhibits
high clinical response rates in patients with relapsed or
refractory B-ALL and B-NHL [5, 6], it still has some lim-
itations due to its low molecular weight (~55 kDa),
which is below the glomerular filtration threshold [6].
Therefore, blinatumomab is administered over a 28-day
continuous infusion using a mini-pump in order to
maintain steady drug concentration [6], which results in
inconvenience for patients and an increased possibility
of treatment-related adverse event. To overcome the
drawback of short half-life, Kipriyanov and his colleagues
[7] firstly designed a tetravalent bispecific tandem dia-
body (TandAb) with two binding sites for CD3 and two
for CD19. Due to the TandAb’s large molecular weight
(~105 kDa), it is not subject to glomerular filtration. In
addition, the molecule exhibits stability properties with a
half-life ranging from 18.4 to 22.9 h after intravenous
administration in mice [8].
Most of therapeutic antibodies are administrated by
intravenous infusion, which results in a handful of anti-
bodies that can reach the tumor sites. Thus, introducing
an efficient and targeted delivery system for these thera-
peutic antibodies may enhance the efficacy of treatment
for tumors, especially for minimal residual diseases
(MRD) [9]. Mesenchymal stromal cells (MSCs) are at-
tractive cellular vehicles for the therapy of malignant
diseases as they have the ability to migrate into tumors
and track microscopic metastasis [10, 11]. We have pre-
viously employed human umbilical cord-derived MSCs
(UC-MSCs) as carriers for gene therapy [12, 13] because
UC-MSCs are easier to isolate and expand, and the har-
vesting procedure is more consistent and yields a greater
number of relevant cells than other adult and feta tissues
[14]. These characteristics indicate that UC-MSC is a
promising targeted delivery system with anticancer
agents for a variety of cancers.
However, a study from Ribeiro and his colleagues
shows that MSCs derived from different tissues possess
different immunosuppression capabilities and their ac-
tion varies with the immune cell type [15]. Thus, MSCs
are actually a double-edged sword when employed as
carriers with agents triggering cytotoxicity of T cells for
tumors. Although the exact mechanisms of MSC-
mediated immunosuppression are still debated, many
different factors are believed to be involved. It has been
revealed that indoleamine 2,3-dioxygenase (IDO), the
first and rate-limiting enzyme in the degradation of tryp-
tophan [16], plays a role in human MSCs to regulate im-
munity in tumor microenvironment [17]. By depleting
tryptophan locally and accumulation of its metabolites
such as kynurenine and quinolinic acid, which could
interact the aryl hydrocarbon receptor (AHR) on T cells,
IDO seems to block the proliferation of T cells and in-
hibit T cell activity [18, 19]. Because IDO is induced by
inflammatory cytokines such as interferon-γ (IFN-γ)
which act through JAK-STAT signaling pathways on
interferon stimulatory response elements (ISRE) and
γ-activating sequences (GAS) in the IDO promoter
[20], its expression is thought to be an endogenous
feedback mechanism controlling excessive immune re-
sponse [21].
In this study, we employed the TandAb platform to
construct a new tandem tetravalent antibody targeting
both CD3 and CD19 (Tandab (CD3/CD19)) using our
own DNA sequences of scFvs. Then, we exploited the
feasibility and efficacy of using genetically modified UC-
MSCs which constitutively secreted Tandab (CD3/
CD19) (MSC-Tandab) for the treatment of human B cell
lymphoma. Our results showed that MSC-Tandab could
induce specific lysis of CD19-positive Raji cells in the
presence of T cells in vitro and reduce xenograft
tumor growth in vivo in combination with D-1-methyl-
tryptophan (D-1MT), an IDO pathway inhibitor [22].
Methods
Cell lines and cell culture
Human embryonic kidney cell-derived 293T cells (kindly
provided by Professor Cheng Tao, PUMC) were main-
tained in DMEM (Invitrogen, USA) supplemented with
2 mM L-glutamine, 100 U/mL penicillin (Gibco, USA),
100 μg/mL streptomycin (Gibco, USA) and 10% FBS
(Gibco, USA). The human acute T cell leukemia cell line
Jurkat, human chronic myelogenous leukemia cell line
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K562, and human B cell lymphoma cell lines Raji, Daudi,
and BJAB (Institute of Hematology and Blood Diseases
Hospital, Chinese Academy of Medical Science and
Peking Union Medical College, Tianjin, China) were
grown in RPMI-1640 medium (Invitrogen, USA) supple-
mented with 2 mM L-glutamine, 100 U/mL penicillin
(Gibco, USA), 100 μg/mL streptomycin (Gibco, USA),
and 10% FBS. The cells were incubated at 37 °C in a hu-
midified atmosphere containing 5% CO2.
PBMC isolation
With informed consent, human peripheral blood mono-
nuclear cells (PBMCs) were isolated from healthy volun-
teers. Details are provided in the Additional file 1.
Construction of lentiviral expression vectors
Plasmids pLH-T3a*-19a (containing a cysteine at pos-
ition Ser-100 of VL3) and pLH-19a-T3a* (containing a
cysteine at position Gly-44 of VH3) encoding for hybrid
VL3-VH19 and VL19-VH3 scFvs [23], respectively, were
used for assembly of Tandab (CD3/CD19) genes. See de-
tails in Additional file 1.
Expression and purification of Tandab (CD3/CD19)
293T cells were transfected with pLentiR-Tandab
(CD3/CD19) or pLentiR-EV using Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer’s
protocol. After 48 h of transfection, supernatants were
collected by centrifugation at 500×g for 10 min at 4 °C to
clear 293T cells. The soluble antibodies in the superna-
tants were purified by 6×His-tag affinity chromatography
(GE Healthcare, Sweden) according to the manufacturer’s
instruction. The purified preparations were quantified
with His-tag ELISA detection kit (GenScript, USA)
and were used for cell-binding assays and cytotoxicity
assays in vitro. In addition, the unpurified or purified
Tandab (CD3/CD19) were verified by Western blot
analysis.
Cell-binding assay
The CD19-positive cell lines Raji, Daudi, and BJAB and
the CD3-positive cell line Jurkat were employed for ana-
lysis of binding activity of Tandab (CD3CD19) by flow
cytometry (LSRII, Becton Dickinson Bioscience, San
Jose, CA). The CD19- and CD3-negative K562 cells were
served as negative control. See details in Additional file 1.
Cytotoxicity assay
All cytotoxicity assays were performed with PBMC ef-
fector cells. And PBMCs were pre-activated with
50 IU/mL IL-2 for 3 days before cytotoxicity assays.
CD19+ cells (Raji, Daudi, and BJAB) and CD19− cells
(K562) were prepared as target cells. The specific lysis of
target cells was detected by LDH release assay according
to the manufacturer’s protocol. See details in Additional
file 1.
MSCs preparation
MSCs were isolated from human umbilical cord
Wharton’s jelly (WJ) as previous described [24]. MSCs
were cultured at a density of 8 × 103 cell/cm2 in DF-12
medium (Invitrogen, USA) supplemented with 2 mM
L-glutamine and 10% FBS (Gibco, USA). When cells
reached 80~90% confluence, they were detached using
a 0.125% trypsin/1 mM EDTA solution and re-seeded
using the same growth medium for subsequent passages.
For all experiments, early passages MSCs (3P to 5P) were
used.
Production of lentivirus
The lentiviral particles carrying Tandab (CD3/CD19)
gene were packaged according to the SBI’s protocol. See
details in Additional file 1.
Transduction of MSCs and viability of transduced MSCs
The transduction of MSCs was performed as previously
reported [12]. And viability of transduced MSCs was de-
tected by MTT assays. See details in Additional file 1.
Immunophenotype profile and tri-lineage differentiation
of MSCs
MSCs and transduced MSCs (including MSC-EV and
MSC-Tandab) were trypsinized (0.125% trypsin-EDTA)
and washed twice with PBS, then incubated with APC-
labeled anti-human CD73, CD90, CD105, CD14, CD19,
CD34, CD45, and HLA-DR (all from BD Biosciences)
for 30 min. After washing with PBS, the expression level
of these molecules was determined by flow cytometry.
To test the in vitro differentiation ability, MSCs or
transduced MSCs were cultured in adipogenic, osteo-
genic, and chondrogenic differentiation medium, re-
spectively. For adipogenic differentiation, the MSCs were
maintained in medium containing 1 mM dexametha-
sone, 500 μM IBMX, 10 μg/mL insulin, and 60 μM indo-
methacin (all from Sigma). Three weeks later, the cells
were fixed and stained with Oil Red O (Sigma). For
osteogenic differentiation, cells were cultured in IMDM
(Gibco) supplemented with 10% FBS, 100 nM dexa-
methasone, 50 μg/mL ascorbic acid, and 10 μM β-
glycerophosphate (all from Sigma) for about 3 weeks. At
the end of incubation, the cells were assayed by Alizarin
Red S (Sigma) staining for calcium deposition. To induce
chondrogenic differentiation, MSCs were maintained in
medium with 100 nM dexamethasone, 50 μg/mL ascor-
bic acid, 40 μg/mL proline, 10 ng/mL TGF-β3, 2 mM
ITS, 53.5 μg/mL lindeic acid, and 12.5 μg/mL BSA (all
from Sigma). Three weeks later, the cultured cells were
stained with Alcian Blue (Sigma). In addition, RNA was
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isolated from cells after the induction, and the expres-
sion level of differentiation-related gene was determined
by real-time PCR on an ABI Prism 7500 detection sys-
tem (Applied Biosystems, USA). And primers used for
real-time PCR were summarized in Table 1.
In vitro and in vivo MSC migration assay
In vitro and in vivo MSCs migration assays were per-
formed as previously reported [12, 25]. Details are pro-
vided in Additional file 1.
In vitro co-culture killing experiments
To assess the bioactivity of Tandab (CD3/CD19) se-
creted by MSCs, a co-culture system using transwell
plates with 0.4-μm-pore membrane was established. The
specific lysis of target cells was determined by FACS
analysis according to the “calcein-loss” method [26].
Briefly, MSC-Tandab, MSC-EV, or MSCs were seeded
into 6-well culture plates at a density of 1 × 105 cells per
well and incubated for 72 h. Then, Raji cells labeled with
calcein-AM (Sigma, USA) and pre-activated PBMCs
were added to the equilibrated inserts at an E:T ratio of
10:1. After co-cultured for 24 h, the cells in the inserts
were harvested to be detected by flow cytometry. The
expression of activation surface markers CD69 and
CD25 of T cells was detected by flow cytometry in the
same conditions of co-culture system with unlabeled
Raji cells. And the supernatants in the inserts were col-
lected for the assay of cytokines produced in the co-
culture system, including IL-2, IFN-γ, and TNF-α using
ELISA kits (R&D system, USA).
Because of expression of IDO in MSCs induced by
IFN-γ in the co-culture system, we performed a co-
culture experiment for a longer time in absence or pres-
ence of D-1MT (Sigma-Aldrich, USA), which is an IDO
pathway inhibitor. As mentioned above, MSC-Tandab,
pre-activated PBMCs, and Raji cells were added respect-
ively into the co-culture system with or without 1 mM
D-1MT and co-cultured for 24, 48, and 72 h. Cells in the
upper chamber were harvested at the indicated time
points. And the residual Raji cells were determined by
flow cytometry with FITC-conjugated anti-CD19 anti-
bodies. The supernatants were harvested for the meas-
ure of kynurenine, a metabolite of tryptophan in the
IDO pathway. Repetitive wells were set for detection of
CD98 and Jumonji in the messenger RNA (mRNA) level
at different time points (24, 48, and 72 h) by real-time
PCR. In addition, the proliferation of T cells in the co-
culture system was detected by BrdU Flow Kit (BD
Bioscences). Details are provided in Additional file 1.
Inducible expression of IDO in MSCs
MSCs were seeded into 6-well culture plates at a density
of 1 × 105 cells per well in the absence or presence of
20 ng/mL of recombinant human IFN-γ (R&D system,
USA). After incubation for 48 h, expression of IDO in
the level of mRNA or protein upon treatment with
IFN-γ was verified by real-time PCR and Western
blot analysis.
Detection of kynurenine
Because IDO catalyzes the metabolism of tryptophan in
the kynurenine pathway, the activity of IDO was deter-
mined by spectrophotometric assay for kynurenine [17]
in supernatants from co-culture system and cultures of
MSCs with or without exogenous IFN-γ stimulation. See
details in Additional file 1.
Cell viability assay
Cell viability assay was performed by MTT assay (Sigma-
Aldrich, USA). See details in Additional file 1.
Western blot analysis
The expression of specific protein was detected by
Western blot analysis. See details in Additional file 1.
Real-time PCR
Total RNA was extracted from corresponding cells using
Trizol reagent (Invitrogen, USA) following the manufac-
turer’s protocol. The complementary DNA (cDNA) was
generated using OligdT primers and M-MLV reverse
Table 1 Primer sequences for genes in real-time PCR
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transcriptase (Invitrogen, USA) with 2 μg total RNA.
Real-time PCR was performed using ABI Prism 7500
real-time PCR system (Applied Biosystems, USA), in
combination with SYBR Green (Takara, Dalian, China).
Specific primers for each gene (Table 1) were selected
using Primer Express (Applied Biosystems, USA). Rela-
tive transcript expression was normalized to that of
GAPDH mRNA.
Growth inhibition of B cell lymphoma xenografts in vivo
All animal studies were performed in accordance with
the guidelines under the Animal Ethics Committee of
the Institute of Hematology and Hospital of Blood
Diseases, Chinese Academy of Medical Sciences and
Peking Union Medical College. Raji cells (2 × 107 cells
per mouse) were implanted subcutaneously into the
right flank of each BALB/c nude mice (female, 5–6
weeks of age; PUMC, China) 1 day after the application
of total body irradiation (300 cGy). One week later when
tumor size reached 100–200 mm3, the mice were treated
intravenously with MSC-Tandab and pre-activated
PBMCs and D-1MT in the drinking water. Then, the
mice were sacrificed for analysis of organ damages in
the indicated time. In tumor therapy experiments,
the mice were randomly divided into six groups (five
mice for each group) as follows: (a) MSC + PBMC;
(b) MSC-EV + PBMC; (c) MSC-Tandab + PBMC; (d)
MSC + PBMC+D-1MT; (e) MSC-EV + PBMC+D-1MT;
(f) MSC-Tandab + PBMC+D-1MT. MSCs (1 × 106 cells
per mouse) were injected intravenously at day 0, followed
by pre-activated PBMCs (5 × 106 cells per mouse) via the
vein 2 days later, every 7 days for 2 weeks. The mice were
treated with or without D-1MT (2 mg/mL in drinking
water) from the beginning to the end of the treatment. At
day 21 after treatment started, the mice were sacrificed by
cervical dislocation under anesthesia. Then, tumor tissues
were harvested and weighted for treatment evaluation.
Statistical analysis
Data are represented as mean ± SD. Statistical analysis
was performed using GraphPad Prism 6 or Microsoft
Excel software. Significance was assayed by an unpaired
two-tailed Student t test or ANOVA (*P < 0.05, **P < 0.01,
***P < 0.001).
Results
Design and production of Tandab (CD3/CD19)
The concept of dimerizing scFv fragments having a short
peptide linker between the domains to create two
antigen-binding sites pointing in opposite directions [27]
was extended to single-chain molecules containing four
antibody variable domains [8]. We previously con-
structed a CD3 × CD19 bispecific diabody comprising
two hybrid scFv fragments: an anti-human CD3 VL
domain connected to an anti-human CD19 VH domain
by a short linker peptide (Gly-Gly-Gly-Gly-Ser, G4S) and
anti-CD19 VL connected to an anti-CD3 VH by a similar
linker [23]. We have now fused these hybrid svFvs into a
single-chain polypeptide using a long (G4S)3 linker
(Fig. 1a). The fusion gene fragment VL3-VH19-VL19-VH3
was inserted into a lentiviral expression vector under the
control of constitutively active SV40 promoter. A hexa-
histidine-tag (His6-tag) was added to the carboxyl
terminus of the construct to aid in the detection and
purification of the products. Upon expression, two poly-
peptide gene products dimerize in a head-to-tail fashion.
These active homodimers (Tandab (CD3/CD19)) have
two binding sites for CD3 and two for CD19 (Fig. 1b).
To verify the formation of this gene products, Tandab
(CD3/CD19) was firstly expressed in adherent 293T
cells. In the culture supernatant, protein with a molecu-
lar weight of 106 kDa was detected on non-reducing sta-
tus, and a 53-kDa protein was also detected under the
reducing status (Fig. 1c). As shown in Fig. 1d, Tandab
(CD3/CD19) maintained a dimer formation after puri-
fication in the natural state. Because of the interac-
tions between molecules, a band at 212 kDa was
exposed, which indicated that part of the products
were tetramers.
Tandab (CD3/CD19) binds specifically both to its target
antigens
Binding specificities of the Tandab (CD3/CD19) were
shown by flow cytometry analysis on a number of differ-
ent CD19-positive B cell lymphoma cell lines, including
Raji, Daudi, and BJAB, and CD3-positive Jurkat cells.
No binding was detectable on chronic myelogenous
leukemia cell line K562, which expresses neither CD19
nor CD3 (Fig. 1e). Furthermore, Tandab (CD3/CD19) was
able to significantly prevent parental monoclonal anti-
bodies HIT19a [28] or HIT3a [29] from binding to Raji,
BJAB, Daudi, or Jurkat cells, respectively, in a competitive
binding assay (Fig. 1f).
Tandab (CD3/CD19) mediates specific target cell lysis in
combination with PBMCs
To investigate the tumor lysis mediated by Tandab
(CD3/CD19) in the presence of activated human T cells,
a nonradioactive cytotoxicity assay was performed. For
this purpose, a panel of CD19-positive cell lines of B cell
lymphoma was used as targets with PBMC: target cell
ratios ranging from 20:1 to 1:1. Tandab (CD3/CD19)
was added at a concentration of 8 pmol/mL and after an
8-h reaction time, the target cell lysis was measured by
LDH release described previously [30]. Although CD19-
negative K562 cells were also lysed (less than 30% at the
highest E:T ratio), which may result from aspecific ef-
fects, Tandab (CD3/CD19) produced significant specific
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Fig. 1 Design, production, and biological function of bispecific tetravalent tandem diabody Tandab (CD3/CD19). a Schematic representation of
lentiviral expression vector for Tandab (CD3/CD19). LTR, long terminal repeats; SV40, SV40 promoter; SP, signal peptide, a murine kappa light-
chain leader peptide; G4S, Gly-Gly-Gly-Gly-Ser residues; His6, hexa-histidine tag. b Molecular model of Tandab (CD3/CD19). Upon expression, two
polypeptide gene products dimerize in a head-to-tail fashion. c Tandab (CD3/CD19) was determined by Western blot analysis. The supernatants
from 293T cells after transfection with lentiviral expression vectors were harvested and assayed for Tandab (CD3/CD19) with or without β-
mercaptoethanol (BME) using anti-His tag antibodies. Lane 1, 293T cells transfected with empty vector (negative control); lane 2, 293T cells
transfected with vector expressing Tandab (CD3/CD19). d Western blot analysis of the purified Tandab (CD3/CD19). e Binding specificities of
Tandab (CD3/CD19) to tumor cell lines. FACS analysis with the Tandab (CD3/CD19) on different CD19-positive B cell lines (Raji, Daudi, and BJAB),
on CD3-positive Jurkat cells, and on the CD3- and CD19-negative K562 cells. a, negative controls with the secondary antibody anti-His-Alexa Fluor
488 alone; b, Tandab (CD3/CD19). f Competitive binding activity with FITC-conjugated HIT19a or PE-conjugated HIT3a. Cells were firstly incubated
with Tandab (CD3/CD19) for 1 h at 4 °C, then incubated with FITC-conjugated HIT19a or PE-conjugated HIT3a for 30 min at 4 °C before detection.
a, Negative controls; b, FITC-conjugated HIT19a or PE-conjugated HIT3a alone; and c, Tandab (CD3/CD19) + FITC-conjugated HIT19a or PE-
conjugated HIT3a. Results are representative of three independent experiments. g Specific lysis of malignant target cell lines mediated by Tandab
(CD3/CD19). Cytotoxicity of IL-2 pre-activated PBMCs induced by Tandab (CD3/CD19) with the same concentration (8 pmol/mL) in different
effector to target (E:T) ratios ranging from 20:1 to 1:1 against CD19-positive B cell lines (Raji, Daudi, and BJAB) was detected by LDH release assay
(left panel). Specific lysis of target cells by Tandab (CD3/CD19) with different concentrations at the same E:T ratio (20:1) was also determined (right
panel). K562 cells were served as negative controls. *P < 0.05; **P < 0.01; ***P < 0.001 compared with the corresponding K562 group. Data shown
are the mean ± SD of three independent experiments
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lysis of CD19-positive Raji cells, as well as the Daudi
and BJAB cells (Fig. 1g). Furthermore, target cells were
also lysed efficiently at the same E:T ratio (20:1) with
different concentrations of Tandab (CD3/CD19) (Fig. 1g).
Lysis of target cells induced by Tandab (CD3/CD19)
proceeded in a dose-dependent manner, in which in-
creasing the ratio of E:T or the concentration of Tandab
(CD3/CD19) resulted in enhanced cytotoxicity. These
results are in accordance with our earlier report on dia-
body of antiCD19/antiCD3 [23].
MSCs can be successfully transduced to release Tandab
(CD3/CD19)
MSCs were isolated from human umbilical cord and
identified according to previous reports [24, 25]. Then,
MSCs were transduced with lentivirus encoding Tandab
(CD3/CD19) with copGFP (MSC-Tandab) or alone
copGFP (MSC-EV). The morphology of these cells and
their transduction efficiency (indicated by copGFP) are
shown in Fig. 2a. The transduction efficiency was also
assessed by FACS analysis, which indicated that more
than 73% of the MSCs were successfully transduced
(Fig. 2b). And no significant alterations in cell survival
were observed among MSC-Tandab, MSC-EV, and wide-
type MSCs (Fig. 2c). Western blot results demonstrated
that Tandab (CD3/CD19) was highly expressed in MSC-
Tandab but not in MSC-EV (Fig. 2d). Additionally, the
Tandab (CD3/CD19) released in the supernatants in cul-
ture of MSC-Tandab was detected by ELISA. The level
of secreted Tandab (CD3/CD19) achieved a peak at day
9 (8247.2 ± 796.7 pg/mL) and was detectable even at day
15 after transduction (Fig. 2e). And there was no differ-
ence on surface markers between MSCs and transduced
MSCs (Additional file 2: Fig. S1A). In addition, gene-
modified MSCs maintained their ability of tri-lineages
differentiation (Additional file 2: Fig. S1B and C).
Homing property of MSCs to B cell lymphoma in vitro
and in vivo
MSCs and gene-modified MSCs were previously proved
to have a homing predisposition to tumor cells in vitro
and to the tumor site in models of hepatocarcinoma with
HepG2 cells or lymphoma with BJAB cells [12, 13, 25]. To
investigate the migration capacity of transduced MSCs to
another B cell lymphoma cell line (Raji cells) in this study,
migration assays in vitro using transwell plates were
Fig. 2 Constitutive expression of Tandab (CD3/CD19) in MSCs. MSCs were transduced with lentivirus coding Tandab (CD3/CD19) at 8 MOI for
12 h. Then, supernatants were removed, and fresh medium culture was added. a The representative images depicted the infection efficiency of
MSCs with lentivirus. Forty-eight hours after infection, MSCs carrying copGFP were observed under fluorescent field (upper panel) and bright field
(lower panel), scale bar = μm. MSC-Tandab, MSCs transduced with lentivirus coding Tandab (CD3/CD19); MSC-EV, MSCs transduced with empty
lentivirus. b FACS analysis of percentages of copGFP-positive MSCs. c Cell survival of MSCs transduced with or without lentivirus were detected
by the MTT assay. d Western blot analysis was employed to determine the protein expression of Tandab (CD3/CD19) in MSCs with anti-His tag
antibodies after 5 days of transduction. GAPDH, served as a loading control; BME, β-mercaptoethanol. e Transduced MSCs secreted Tandab (CD3/
CD19) constantly. MSC-Tandab and MSC-EV were cultured in a 24-well plate (4 × 104/well). And the level of Tandab (CD3/CD19) released into
culture was measured by ELISA in the indicated time. Data shown are the mean ± SD of the three repeated experiments
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performed. Culture medium (CM) without Raji cells was
served as a negative control of chemotaxis, and unmodi-
fied MSCs were used as a positive control of migrating
cells. We confirmed that the transduced MSCs migrated
towards Raji cultures in a similar pattern as unmodified
MSCs (Fig. 3a, b). These results indicated that human B
cell lymphoma Raji cells were able to stimulate the migra-
tion of MSCs and the migration capacity of MSCs was not
affected by infection of lentivirus.
In order to verify the homing ability of MSCs in vivo,
we designed a lentiviral vector (pLeniR-Luc) harboring a
firefly luciferase reporter gene (Fig. 3c). MSCs labeled
with luciferase (MSC-Luc) were analyzed at first ex vivo
using bioluminescence imaging (BLI) system (Fig. 3d),
which suggested that luciferase reporter gene could be
used to quantify transplanted MSCs in small living
animals. Then, MSC-Luc (1 × 106 cells per mouse) was
injected intravenously into BALB/c nude mice with
established subcutaneously tumor with Raji cells. BLI re-
vealed that MSCs migrated and selectively accumulated
at the tumor site at 24 h after injection although part of
MSCs was hijacked in the lungs, in which the signal de-
creased as time went on (Fig. 3e). The strongest signal
in the tumor site was observed on day 2, and it was out
of detectable on day 5 (Fig. 3e). During the monitoring
process, MSCs were not traced in other tissues.
MSC-Tandab exhibits cytotoxicity against CD19-positive
Raji cells
To confirm the bioactivity of secreted Tandab (CD3/
CD19) from MSC-Tandab, the co-culture system using
transwell plates with 0.4-μm-pore membrane (cells could
not pass through) was designed. MSC-secreting Tandab
(CD3/CD19), concentration of which could reach
Fig. 3 Migration capacity of MSCs to B cell lymphoma in vitro and in vivo. a Representative photographs showed the migrated MSCs stained
with crystal violet in vitro migration assays. Culture medium (CM), served as a negative control. Scale bar = 200 μm. b The numbers of migrated
MSCs in three independent assays were expressed as mean ± SD. c Schematic representation of lentiviral expression vector for firefly luciferase (Luc).
d MSC-Luc expressed Luc constitutively in vitro. e Tropism of MSCs to tumor site. MSC-Luc was intravenously injected into tumor-bearing mice.
The mice were anesthetized in the indicated time and received intraperitoneal injection of D-luciferin at a dose of 150 μg of D-luciferin per gram
of body weight. Ten minutes later, the BLI for luciferase activity was detected by Xenogen in vivo imaging system. M1, M2, M3: represented
three mice
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(0.1516 ± 0.0283) pmol/mL, in the lower chamber could
pass through the membrane followed by triggering reac-
tions between PBMCs and Raji cells (E:T = 10:1). After
incubation for 24 h, obviously lysis (60.6 ± 5.7%) of Raji
cells was detected by flow cytometry (Fig. 4a). The ex-
pression levels of the early T cell activation marker
CD69 and of the late activation marker CD25 on CD3-
posivitve cells were also assessed (Fig. 4b). Since the
increase of cytokines concentration is the response of
T cells activation and cytotoxicity, classic cytokines
including IL-2, IFN-γ, and TNF-α were measured as
an example to evaluate the activation efficacy of T
cells in the co-culture system. The concentrations of
IL-2, IFN-γ, and TNF-α were (708.27 ± 36.16) pg/mL,
(30.31 ± 2.69) ng/mL, and (60.66 ± 8.21) pg/mL in the
supernatant, respectively, all of which were signifi-
cantly higher than that of the control groups (P < 0.001)
(Fig. 4c–e). These data suggest that MSC-Tandab can trig-
ger cytotoxicity to CD19-positive tumor cells in the pres-
ence of effector cells.
The cytotoxicity induced by MSC-secreting Tandab
(CD3/CD19) can be enhanced by IDO pathway inhibitor
D-1MT
Although we have demonstrated that CD19-positive
tumor cells could be killed efficiently by T cells in the
co-culture system, the presence of MSCs should be in
consideration because of their great immune-modulating
capacity. Some earlier reports have indicated that IDO
plays a pivotal role in MSC-mediated immunosuppres-
sion [17, 31, 32] because IDO expression by human
MSCs occurs only after exposure to inflammatory cyto-
kines such as IFN-γ [31, 33], which produced massively
by T cells during the co-culture assays. For this reason,
an IDO pathway inhibitor D-1MT was employed in our
study to overcome the immunosuppression induced by
MSCs. We firstly verified the inducible expression of
IDO in MSCs with stimulation of exogenous IFN-γ.
After stimulation with IFN-γ (20 ng/mL) for 48 h, the
expression of IDO were detected at the mRNA level and
protein level (Fig. 5a, b). Furthermore, the enzymatic ac-
tivity of IDO (indicated by concentration of kynurenine,
a metabolism of tryptophan) was measured (Fig. 5c). We
next determined whether D-1MT had any cytotoxicity
on MSCs, Raji cells, or PBMCs. Results from the cell
proliferation assays suggested that no obvious influences
were caused by D-1MT on those cells (Fig. 5d). Based
on these results, we then performed a co-culture killing
experiment again in the same conditions described
above in the absence or presence of D-1MT (1 mM) for
24, 48, and 72 h. As shown in Fig. 5e, the number of
residual Raji cells decreased significantly at 48 and 72 h
(P < 0.05). However, there was no significant difference
at the first 24 h.
Fig. 4 Cytotoxicity of T cells to Raji cells mediated by Tandab (CD3/CD19) secreted from MSCs. In order to evaluate the function of
MSCs-secreting Tandab (CD3/CD19), a co-culture system using transwell plates with 0.4-μm-pore membrane was established. MSCs were
plated into 6-well plates with a density of 1 × 105 cells per well after transduced with lentivirus. Seventy-two hours later, Raji cells were
labeled with calcein-AM (5 μM). Then, PBMCs and labeled Raji cells (E:T=10:1) were added to the equilibrated inserts. After co-cultured for
24 h, cells in the inserts were harvested to be detected by FACS. a The specific lysis of Raji cells. b Activation surface markers CD69 and
CD25 of T cells. c–e Cytokines including IL-2, IFN-γ, and TNF-α in the supernatant were measured using ELISA kits. PR, PBMC + Raji; MPR,
MSC + PBMC+Raji; MPR-EV, MSC-EV + PBMC+Raji; MPR-Tandab, MSC-Tandab + PBMC + Raji. ***P< 0.001 compared with PR group. Data
shown are the mean ± SD of the three repeated experiments
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To further investigate the mechanism of D-1MT exerted
in the increasing cytotoxicity, we firstly pointed to the
level of kynurenine which had no changes from 24 to 72 h
(Fig. 5f). Previously, reports show that D-1MT can act as a
mimetic of tryptophan in the sufficiency pathway, thereby
functionally reversing the effects of IDO on formation of
T cell anergy controlled by PKC-θ [22]. We therefore ex-
amined the effect of D-1MT on the expression of anergy-
associated genes in T cells, including CD98 and Jumonji
[34]. Both of the expression of CD98 and Jumonji in T
cells from the co-culture system were up-regulated at
72 h, but this effect was reversed efficiently by D-1MT
(Fig. 5g). Interestingly, the proliferation of T cells in the
co-culture system was also partly restored by D-1MT at
48 and 72 h, respectively (Fig. 5h).
Antitumor potential of MSC-Tandab in combination with
D-1MT against Raji xenograft tumors
We further investigated the antitumor potential of MSCs
engineered with Tandab (CD3/CD19) in combination
Fig. 5 IDO pathway inhibitor D-1MT enhances the cytotoxicity induced by MSC-secreting Tandab (CD3/CD19) in vitro. a IDO mRNA expression in
MSCs stimulated with IFN-γ. MSCs were cultured in the absence or presence of exogenous IFN-γ (20 ng/mL). Cells were harvested after 2 days in
culture, total mRNA was extracted, and IDO message was assayed by real-time PCR. b IDO protein was determined by Western blot analysis. MSCs
were harvested after cultured for 48 h, as in a, and total cell lysates were assayed for IDO protein. Results are representative of three independent
experiments. c To determine enzyme activity of IDO, MSCs were cultured with or without IFN-γ (20 ng/mL) stimulation for 48 h. IDO enzyme
activity was evaluated by spectrophotometric detection of the tryptophan metabolite, kynurenine, a product of IDO catabolism. d Influence of
D-1MT on the proliferation of cells (Raji, PBMCs and MSCs). Cells were seeded in 96-well plates and treated with different concentrations of
D-1MT (0–2000 μM) for 72 h. Cell proliferation was determined by MTT assay, and the y axis represents cell proliferation as a percent of the
control. e D-1MT promotes the specific lysis of Raji cells induced by MSC-secreting Tandab (CD3/CD19). MSCs, Raji cells, and PBMCs were
co-cultured as mentioned above with or without D-1MT (1 mM) for 24, 48, and 72 h. The residual Raji cells were detected by FACS with FITC-
conjugated anti-CD19 antibodies. D-1MT, D-1-methyl-tryptophan. f Determination of kynurenine in the supernatant from the co-culture system.
g Analysis of anergy-associated genes expression of CD98 (left panel) and Jumonji (right panel). The cells in the inserts were harvested in the
indicated time. Total mRNA was extracted, and the messages of CD98 and Jumonji were assayed by real-time PCR. NS, normal saline. h Relative
proliferation of T cells. The cells were harvested in the indicated time. Proliferation of T cells was detected using BrdU flow kit. The proliferation of
T cells in PR group (without MSCs) was served as a reference. *P < 0.05 compared with the control group; ***P < 0.001 compared with the control
group. Data shown are the mean ± SD of the three repeated experiments
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with D-1MT in BALB/c nude mice subcutaneously im-
planted with Raji cells. Firstly, to ascertain the safety of
this therapeutic schedule, tumor-bearing mice were
treated with MSC-Tandab, PBMCs, and D-1MT. Results
from pathological reports indicated that this treatment
did not cause organ damages, such as the lung, liver,
spleen, and kidney (Fig. 6a). Then, we begun the formal
therapeutic experiments. When the tumor size reached
100–200 mm3, the tumor-bearing mice were grouped
and treatments were started according to the scheme
shown in Fig. 6b. The animals were sacrificed on day 21,
and tumor tissues were dissected and weighed for ana-
lysis. Interestingly, compared with the mice in the con-
trol group (treated with MSC-EV + PBMC), the mice
treated with MSC-Tandab and PBMCs exhibited no evi-
dent tumor regression (Fig. 6c). However, the tumor
weight of the mice treated with MSC-Tandab and
PBMCs combined with D-1MT decreased 61.2% (Fig. 6c).
In addition, no obvious changes in the body weight of
the mice were observed during the treatment (Fig. 6d).
Discussion
Application of MSCs to serve as vehicles for delivering
TandAb to tumor has not been reported so far. In this
study, we investigated the therapeutic effects of gene-
modified MSCs with Tandab (CD3/CD19) for B cell
lymphoma. The hypothesis is that engineered MSCs
which injected intravenously into the tumor-bearing
mice would specifically migrate to tumor site and secrete
Tandab (CD3/CD19) which recruits T cells to exhibit a
potent antitumor immunity in combination with an IDO
pathway inhibitor D-1MT. And results presented here
support the feasibility of this strategy.
Currently, two approaches have been developed to
harness T cells for killing tumor cells. The first approach
utilizes gene-modified T cells with an engineered
chimeric antigen receptor (CAR) combining a desired
antigen-recognition fragment of a monoclonal antibody
against T cell activation domains from the T cell receptor
complex, such as the ζ chain, with co-stimulatory mole-
cules, from CD28, 4-1BB, or OX40 [35]. The other
Fig. 6 Tumor suppressing effects of MSC-Tandab in combination with D-1MT against B cell lymphoma in mice. a Histological analysis in organs
from mice. On day 7 after treatment, mice organs including the lung, liver, spleen, and kidney were dissociated for fixation and HE staining. Scale
bar = 100 μm. b Experimental protocol of the tumor therapy. BALB/c nude mice were injected subcutaneously with Raji cells (2 × 107 per mouse)
into the right flank. Seven days later (day 0), MSCs (1 × 106 per mouse) were injected intravenously into the xenograft Raji tumor-bearing mice.
Mice received intravenous injection of PBMCs (5 × 106 per mouse) on day 2. And mice were treated with or without D-1MT (2 mg/mL in the
drinking water) along the treatment. The second treatment was received on day 7. All mice were sacrificed on day 21. c The tumor weights of
different groups were measured in the end of treatment. d Changes in the body weight of Raji lymphoma xenograft models during the
treatment. NS, no significance; **P<0.01; ***P<0.001
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approach depends on T cell recruitment via bispecific
antibodies (bsAbs) [36] which bind one arm to T cell ac-
tivation domain and bind the other arm to a tumor-
associated antigen on the target cell. We previously con-
structed an anti-CD3 × anti-CD19 bispecific antibody,
which could efficiently redirect T cells to lysis both B
cell lymphoma cell lines and patient-derived B-ALL cells
[23, 37]. In this study, we successfully constructed a new
tandem diabody with two binding sites for CD3 and two
for CD19 using the DNA sequences from our anti-
CD3 × anti-CD19 bispecific antibody. The relative
amount of tandem diabodies proved to be dependent
on the length of the linker in the middle of the chain
[7]. It was reported that the middle linker should not
be too short or too long to force the four domains to
interact with complementary ones of another molecule
with the formation of an eight-domain Tandab [7]. We
therefore chose a linker with 15 amino acid residues in
our construct. In addition, our earlier data have suggested
that the introduced disulfide covalent bond between VH3
and VL3 at rational positions could enhance the stability
of fusion proteins [23, 38]. Since the two peptides of
TandAb are held together by non-covalent associations of
the corresponding VH and VL domains, an extra disulfide
bond can prevent the peptide diffusing away from the
other one. Results from Western blot analysis suggested
that nearly no monomers were detectable in the non-
reducing condition. However, we also observed a band in
212 kDa in the non-reducing condition (Figs. 1c, d and
2d), which should be dimers of Tandab (CD3/CD19) with
intermolecular forces. And the amount of them decreased
after purification (Fig. 1d). Furthermore, data from cell-
binding assays and cytotoxicity assays in vitro indicated
that our Tandab (CD3/CD19) could bind to both of CD3-
positive cells and CD19-positive cells and induce the spe-
cific lysis of CD19-positive cells.
MSCs hold great promise for clinical applications in
the treatment of various diseases owing to their multi-
lineage differentiation potential and immunosuppressive
properties. Furthermore, the tumor tropism property of
MSCs has led to the utilization of them as attractive de-
livery vehicles for a spectrum of antitumor agents
against cancers [39–43]. Several previous investigations
reported by our laboratory also support feasibility of this
strategy [12, 13, 25, 44]. In the present study, we engi-
neered the human umbilical cord-derived MSCs through
transduction by lentivirus to secrete Tandab (CD3/
CD19). We demonstrated that the MSC-Tandab could
maintain their properties after lentiviral infection, in-
cluding their surface markers, tri-lineage differentiation,
proliferation, and the capacity to migrate towards tumor
cells in vitro. Additionally, the tropism towards tumor-
bearing mice with Raji cells was confirmed by in vivo
imaging system with luciferase-labeled MSCs (Fig. 3e).
These findings indicate that UC-MSCs can be used as
ideal vehicles to deliver Tandab (CD3/CD19) to tumor.
Furthermore, to mimic the therapeutic process with
MSC-Tandab in vivo, we designed a co-culture system
using transwell plates mentioned above, in which Tandab
(CD3/CD19) secreted from MSC-Tandab could migrate
to the upper insert to trigger cytotoxicity of T cells
against CD19-positive cells. Results from the specific
lysis of Raji cells and released cytokines confirmed our
initial hypothesis. However, it has been reported that
various factors are believed to be involved in the mecha-
nisms of MSC-mediated immunosuppression, including
inducible nitric oxide synthase (iNOS), IDO, tumor ne-
crosis factor-inducible gene 6 (TSG6), CC-chemokine
ligand 2 (CCL2), IL-10, and prostaglandin E2 (PGE2)
[45]. Although the immune-regulatory effects of MSCs
do not occur spontaneously, it should be taken into ac-
count in this study because of the released cytokines,
such as IFN-γ. The expression of IDO in MSCs induced
by IFN-γ might contribute to the immunosuppressive
microenvironment owing to tryptophan depletion and
accumulation of its metabolites. Additionally, MSC-
Tandab shows basal increased levels of kynurenine
(Fig. 5f ), which is associated to an enhanced immuno-
suppression ability. This aspect indicates that we should
pay attention to genetic modification of MSCs since they
could be responsible of an augmented pro-tumoral ef-
fect. Therefore, we employed D-1MT, an IDO pathway
inhibitor which differed from direct enzymatic inhibitors
of IDO, to overcome the inhibition effect of IDO. Data
from the co-culture killing experiments showed that D-
1MT could increase the ratio of lytic cells at a certain
degree. No significant changes on the level of kynure-
nine were observed, which suggested that D-1MT could
not inhibit the enzymatic activity of IDO directly. Then,
we confirmed that the expression of the T cell anergy-
associated genes CD98 and Jumonji were decreased in
the presence of D-1MT. And the proliferation capacity
of T cells was also increased by D-1MT. Furthermore,
the antitumor growth effect of MSC-Tandab in vivo was
enhanced significantly in combination with D-MT. Al-
though IDO is known to be overexpressed in several hu-
man cancers, including prostate, breast, brain, and
hematologic malignancies [46], it is not detectable in
Raji cells even with the stimulation of IFN-γ [47]. While a
study about IDO expression by circulating leukemic cells
from 5 B-CLL patients showed that IDO could not be de-
tected in the PBMCs of any of them, but in four of the
five, IDO was dramatically up-regulated when cells were
cultured with IFN-γ for 24 h [47]. This may be one of the
reasons for drug resistance during the treatment. Thus,
our treatment with MSC-Tandab in combination with
IDO pathway inhibitor D-1MT indicates a new treatment
strategy for refractory and relapse B cell malignancies.
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Conclusions
We have demonstrated in this study that human UC-
MSCs can be acted as cell-based delivery vehicles for the
treatment of B cell lymphoma. Tandab (CD3/CD19) se-
creted from UC-MSCs effectively redirected T cells to
inhibit the growth of Raji lymphoma in mouse models in
combination with D-1MT. Our findings indicate that the
use of UC-MSCs as vehicles for engineered-antibodies
combined with immunoregulatory agents represents a
potential clinical application of gene therapy for cancers.
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